1EPI - Études Pharmaco-Immunologie (Université de La Réunion,CHU La Réunion site Félix Guyon, Allée des Topazes, CS11021, 97400 Saint Denis de La Réunion, France - Réunion)
Abstract : The mosquito-borne viral disease dengue is a global public health problem causing a wide spectrum of clinical manifestations ranging from mild dengue fever to severe dengue with plasma leakage and bleeding which are often fatal. To date, there are no specific medications to treat dengue and prevent the risk of hemorrhage. Dengue is caused by one of four genetically related but antigenically distinct serotypes DENV-1–DENV-4. The growing burden of the four DENV serotypes has intensified both basic and applied research to better understand dengue physiopathology. Research has shown that the secreted soluble hexameric form of DENV nonstructural protein-1 (sNS1) plays a significant role in the pathogenesis of severe dengue. Here, we provide an overview of the current knowledge about the role of sNS1 in the immunopathogenesis of dengue disease. We discuss the potential use of sNS1 in future vaccine development and its potential to improve dengue vaccine efficiency, particularly against severe dengue illness.
https://hal.univ-reunion.fr/hal-03703022 Contributor : Réunion UnivConnect in order to contact the contributor Submitted on : Thursday, June 23, 2022 - 3:30:45 PM Last modification on : Tuesday, June 28, 2022 - 3:35:36 PM
Grégorie Lebeau, Alisé Lagrave, Eva Ogire, Lauriane Grondin, Soundary Seriacaroupin, et al.. Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine. Vaccines, MDPI, 2021, 9 (9), ⟨10.3390/vaccines9090946⟩. ⟨hal-03703022⟩